117 completed, 54 unknown, 36 terminated, 17 recruiting. 126 Phase 2, 90 Phase 1, 28 Not applicable, 14 Phase 3, 5 Early Phase 1.
Follow Lymphoma, Extranodal NK-T-Cell: new trials by email Literature Review of Lymphoma, Extranodal NK-T-Cell trials Research Report on Lymphoma, Extranodal NK-T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma Stapokibart, immune checkpoint inhibitor - Lymphoma, NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2026-12-01 | 2026-08-28 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases Extranodal NK/T-cell Lymphoma, Aggressive NK-Cell Leukemia | Recruiting | Rong Tao | 1500 | 2026-08-11 | 2026-08-13 | |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma TR115, Investigator's Choice - PTCL, NK T-Cell Lymphoma | Phase 3 | Not yet recruiting | Tarapeutics Science Inc. | 180 | 2026-07-30 | 2026-06-10 |
| Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma SCA Induction followed by Response-Adapted Therapy - Complete Remission Rate， CRR, Progression Free Survival | Not applicable | Not yet recruiting | Sun Yat-sen University | 30 | 2026-06-01 | 2026-04-21 |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 34 | 2026-05-15 | 2026-04-28 |
| Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma Tislelizumab, Zeprumetostat - Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Rong Tao | 107 | 2026-04-30 | 2026-06-18 |
| Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase - Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 25 | 2026-04-01 | 2026-04-13 |
| Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms JV-394 - Neoplasms | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 33 | 2026-02-18 | 2026-08-12 |
| Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL Golidocitinib + Pegaspargase + Anti-PD-1 mAb - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | LIANG WANG | 40 | 2026-02-10 | 2026-03-09 |
| Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma Golidocitinib in combination with P-GEMOX and PD-1 inhibitor, PD-1 inhibitor in combination with P-GEMOX - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | WEI XU | 40 | 2026-01-25 | 2026-02-04 |
| Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma Thiotepa - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 37 | 2025-12-30 | 2025-12-11 |
| Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma Selinexor, azacitidine - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 39 | 2025-12-30 | 2025-12-11 |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma EBV TCR-T - NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 24 | 2025-09-20 | 2025-12-02 |
| A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. P-GEMD, P-Gemox - NK-T-Cell Lymphoma, Extranodal | Phase 3 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 60 | 2025-05-01 | 2025-05-01 |
| A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma DAPT regimen plus radiotherapy - NK/T Cell Lymphoma | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 57 | 2025-03-21 | 2025-06-03 |
| The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma T-NK Cell Lymphoma | Not yet recruiting | Ruijin Hospital | 50 | 2025-03-01 | 2025-03-07 | |
| The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study T-NK Cell Lymphoma | Not yet recruiting | Ruijin Hospital | 200 | 2025-01-01 | 2024-12-24 |
Showing 20 of 269. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (136) · Lymphoma, Large-Cell, Anaplastic (134) · Burkitt Lymphoma (127) · Immunoblastic Lymphadenopathy (125) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (125) · Lymphoma, Mantle-Cell (120) · Lymphoma, B-Cell, Marginal Zone (119) · Lymphoma, Follicular (119) · Leukemia, Lymphocytic, Chronic, B-Cell (118) · Lymphoma, Non-Hodgkin (116) · Mycosis Fungoides (111) · Sezary Syndrome (111) · Lymphoma, T-Cell, Cutaneous (110) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (110)
Neoplasms by Histologic Type (268) · Neoplasms (258) · Lymphoma, T-Cell (246) · Hemic and Lymphatic Diseases (189) · Lymphatic Diseases (189) · Immunoproliferative Disorders (185) · Immune System Diseases (184) · Lymphoma (181) · Lymphoproliferative Disorders (158) · Lymphoma, Non-Hodgkin (153) · Hematologic Diseases (148) · Leukemia, Lymphoid (144) · Lymphoma, B-Cell (140) · Disease Attributes (137) · Pathologic Processes (137)
fludarabine phosphate (29) · Etoposide (27) · pegaspargase (25) · Cyclophosphamide (23) · Peripheral Blood Stem Cell Transplantation (23) · Mycophenolic Acid (21) · Whole-Body Irradiation (21) · Gemcitabine (20) · Busulfan (19) · Dexamethasone (17) · Methotrexate (17) · Tacrolimus (15) · Cyclosporine (14) · Antilymphocyte Serum (13) · Radiotherapy (12)
National Cancer Institute (NCI) (22) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (11) · Sun Yat-sen University (11) · City of Hope Medical Center (9) · Ruijin Hospital (9) · Beijing Tongren Hospital (7) · Case Comprehensive Cancer Center (7) · Barbara Ann Karmanos Cancer Institute (6) · Samsung Medical Center (6) · Fudan University (5) · Mingzhi Zhang (5) · UNC Lineberger Comprehensive Cancer Center (5) · Wake Forest University Health Sciences (5) · M.D. Anderson Cancer Center (4)
United States (144) · China (72) · South Korea (16) · Italy (11) · Canada (8) · France (8) · Germany (6) · United Kingdom (5) · Singapore (4) · Spain (4) · Japan (3) · Australia (2) · Hong Kong (2) · Switzerland (2) · Taiwan (2)
David Maloney (4) · Rong Tao, MD (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · Thomas C. Shea, MD (3) · Thomas E. Witzig, MD (3) · Won Seog Kim, MD, PhD (3) · Ye Guo, MD (3) · Abhinav Deol, M.D. (2) · Ann Woolfrey (2) · Asad Bashey, MD, PhD (2) · Chuanxu Liu, MD & PhD (2) · Craig C. Hofmeister, MD (2) · George Chen (2)
PMID 32499241, PMID 34806163, PMID 28911074, PMID 34702811, PMID 35489026, PMID 41774854, PMID 18042692, PMID 18327587, PMID 18463792, PMID 18698002, PMID 19238148, PMID 19880495, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20671118, PMID 21123825, PMID 21135857, PMID 21247755, PMID 21498721, PMID 21599590, PMID 21715313, PMID 22259028, PMID 22811078, PMID 23023715, PMID 23393050, PMID 23649469, PMID 24057042, PMID 24142051, PMID 24474568, PMID 24991715, PMID 25113753, PMID 25213183, PMID 25393368, PMID 25921059, PMID 26077240, PMID 26175532, PMID 26202875, PMID 26210287, PMID 26210442, PMID 26213141, PMID 26222726, PMID 26353084, PMID 26424652, PMID 26659919, PMID 26688485, PMID 26700120, PMID 26700123, PMID 26764356
P30CA015704 (12), P30CA015083 (7), P30CA033572 (6), P30CA022453 (5), P30CA072720 (5), P01CA018029 (4), P30CA016086 (4), P30CA036727 (4), U01CA062491 (4), U01CA097452 (4), U10CA032102 (4), P30CA043703 (3), U01CA062487 (3), P01CA078902 (2), P30CA006973 (2)